Harold Roberts

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Clinical experience with activated factor VII: focus on safety aspects
    H R Roberts
    University of North Carolina School of Medicine, Division of Hematology Oncology, Chapel Hill 27599 7035, USA
    Blood Coagul Fibrinolysis 9:S115-8. 1998
  2. ncbi request reprint The use of recombinant factor VIIa in the treatment of bleeding disorders
    Harold R Roberts
    Division of Hematology Oncology, Department of Medicine and The Carolina Cardiovascular Biology Center, 932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 7035, USA
    Blood 104:3858-64. 2004
  3. ncbi request reprint Current concepts of hemostasis: implications for therapy
    Harold R Roberts
    Division of Hematology Oncology, Carolina Cardiovascular Biology Center, University of North Carolina School of Medicine, Chapel Hill 27599 7035, USA
    Anesthesiology 100:722-30. 2004
  4. ncbi request reprint A cell-based model of thrombin generation
    Harold R Roberts
    School of Medicine, Division of Hematology Oncology, Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, North Carolina 27599 7035, USA
    Semin Thromb Hemost 32:32-8. 2006
  5. ncbi request reprint Recombinant factor VIIa: a general hemostatic agent? Yes
    H R Roberts
    Division of Hematology Oncology, Department of Medicine and The Carolina Cardiovascular Biology Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7035, USA
    J Thromb Haemost 2:1691-4. 2004
  6. ncbi request reprint Contributions to the evolution of knowledge about hereditary hemorrhagic disorders
    H R Roberts
    University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 7035, USA
    Cell Mol Life Sci 64:517-21. 2007
  7. ncbi request reprint Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia
    Geoffrey A Allen
    Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Br J Haematol 134:314-9. 2006
  8. ncbi request reprint Safety profile of recombinant factor VIIa
    Harold R Roberts
    Division of Hematology, Center for Thrombosis and Hemostasis, University of North Carolina at Chapel Hill, USA
    Semin Hematol 41:101-8. 2004
  9. ncbi request reprint Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia
    Anna G McDonald
    Duke University, Durham, NC, USA
    Blood 111:2046-8. 2008
  10. pmc Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B
    J Y Chang
    Center for Thrombosis and Hemostasis, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7035, USA
    J Clin Invest 100:886-92. 1997

Research Grants

  1. CELL MEDIATED HEMOSTASIS
    Harold Roberts; Fiscal Year: 1999
  2. CELL MEDIATED HEMOSTASIS
    Harold Roberts; Fiscal Year: 1993
  3. CELL MEDIATED HEMOSTASIS
    Harold Roberts; Fiscal Year: 2004

Collaborators

Detail Information

Publications41

  1. ncbi request reprint Clinical experience with activated factor VII: focus on safety aspects
    H R Roberts
    University of North Carolina School of Medicine, Division of Hematology Oncology, Chapel Hill 27599 7035, USA
    Blood Coagul Fibrinolysis 9:S115-8. 1998
    ..Analysis of these events on a case-by-case basis suggests that rFVIIa is a very safe product with very few side effects. In particular, thromboembolic complications have occurred rarely, if at all...
  2. ncbi request reprint The use of recombinant factor VIIa in the treatment of bleeding disorders
    Harold R Roberts
    Division of Hematology Oncology, Department of Medicine and The Carolina Cardiovascular Biology Center, 932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 7035, USA
    Blood 104:3858-64. 2004
    ..Several questions pertaining to the use of factor VIIa require further investigation, including the mechanism of action; the optimal dose; definitive indications; ultimate safety; and laboratory tests for monitoring therapy...
  3. ncbi request reprint Current concepts of hemostasis: implications for therapy
    Harold R Roberts
    Division of Hematology Oncology, Carolina Cardiovascular Biology Center, University of North Carolina School of Medicine, Chapel Hill 27599 7035, USA
    Anesthesiology 100:722-30. 2004
    ..Finally, recombinant factor VIIa has been used off-label as a hemostatic agent in some surgical situations associated with excessive bleeding that is not responsive to conventional therapy...
  4. ncbi request reprint A cell-based model of thrombin generation
    Harold R Roberts
    School of Medicine, Division of Hematology Oncology, Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, North Carolina 27599 7035, USA
    Semin Thromb Hemost 32:32-8. 2006
    ..We have also shown that activated protein C does not inactivate Va on the platelet surface but rather on endothelial cell surfaces...
  5. ncbi request reprint Recombinant factor VIIa: a general hemostatic agent? Yes
    H R Roberts
    Division of Hematology Oncology, Department of Medicine and The Carolina Cardiovascular Biology Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7035, USA
    J Thromb Haemost 2:1691-4. 2004
  6. ncbi request reprint Contributions to the evolution of knowledge about hereditary hemorrhagic disorders
    H R Roberts
    University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 7035, USA
    Cell Mol Life Sci 64:517-21. 2007
  7. ncbi request reprint Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia
    Geoffrey A Allen
    Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Br J Haematol 134:314-9. 2006
    ..Furthermore, these results suggest that increasing plasma prothrombin concentration prior to rFVIIa administration may offer advantages over the use of rFVIIa alone in the treatment of haemophilic bleeding...
  8. ncbi request reprint Safety profile of recombinant factor VIIa
    Harold R Roberts
    Division of Hematology, Center for Thrombosis and Hemostasis, University of North Carolina at Chapel Hill, USA
    Semin Hematol 41:101-8. 2004
    ..Finally, those situations in which rFVIIa therapy may not be safe, such as disseminated intravascular coagulation (DIC) and sepsis, will also be discussed...
  9. ncbi request reprint Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia
    Anna G McDonald
    Duke University, Durham, NC, USA
    Blood 111:2046-8. 2008
    ..Thus, perivascular TF expression is down-regulated during wound healing. This may prevent thrombosis of neovessels during angiogenesis but renders hemophiliacs vulnerable to hemorrhage during healing...
  10. pmc Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B
    J Y Chang
    Center for Thrombosis and Hemostasis, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7035, USA
    J Clin Invest 100:886-92. 1997
    ....
  11. ncbi request reprint Cloning, expression, and characterization of mouse tissue factor pathway inhibitor (TFPI)
    J Y Chang
    Center for Thrombosis and Hemostasis, University of North Carolina at Chapel Hill, 27599 7035, USA
    Thromb Haemost 79:306-9. 1998
    ..Cloning and expression of the mouse TFPI gene will offer useful information and material for coagulation studies performed in a mouse model system...
  12. ncbi request reprint Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system
    G A Allen
    Department of Pediatrics Department of Pathology and Laboratory Medicine Department of Medicine Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, NC, USA
    J Thromb Haemost 2:402-13. 2004
    ....
  13. ncbi request reprint TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene
    J Y Chang
    Center for Thrombosis and Hemostasis, University of North Carolina, Chapel Hill, USA
    Thromb Haemost 81:45-9. 1999
    ..In addition, heparin does not enhance the inhibition of factor Xa by mouse TFPIbeta although it does accelerate factor Xa inhibition by TFPI...
  14. ncbi request reprint A possible mechanism of action of activated factor VII independent of tissue factor
    D M Monroe
    Department of Medicine, University of North Carolina, Chapel Hill 27599 7035, USA
    Blood Coagul Fibrinolysis 9:S15-20. 1998
    ..We speculate that this platelet-localized thrombin generation may, in part, account for the clinical efficacy of high-dose FVIIa...
  15. ncbi request reprint Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII
    M Hoffman
    Department of Pathology, Durham Veterans Affairs Medical Center, NC 27705, USA
    Blood Coagul Fibrinolysis 9:S61-5. 1998
    ..Activation of FIX and FX on platelet surfaces in thrombocytopenia would result in more thrombin generation per platelet, possibly leading to formation of a stable fibrin network even in the absence of an optimal initial platelet plug...
  16. ncbi request reprint Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets
    D A Gabriel
    Division of Hematology Oncology, The Bone Marrow Transplant Program and The University of North Carolina School of Medicine, Carolina Center for Cardiovascular Biology, Chapel Hill, NC 27599, USA
    J Thromb Haemost 2:1816-22. 2004
    ....
  17. ncbi request reprint The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia
    D M Monroe
    Center for Thrombosis and Hemostasis, UNC School of Medicine, Chapel Hill, North Carolina, USA
    Semin Thromb Hemost 26:373-7. 2000
    ..Finally, enhanced thrombin generation on platelets would mean that fewer platelets are required for hemostasis...
  18. ncbi request reprint Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures
    H A Cooper
    Department of Paediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7220
    Haemophilia 7:517-22. 2001
    ....
  19. ncbi request reprint Recombinant factor VIIa (Novoseven) and the safety of treatment
    H R Roberts
    University of North Carolina, Chapel Hill, NC, USA
    Semin Hematol 38:48-50. 2001
    ..Moreover, in the majority of cases, thrombotic events appear to be caused by improvements in the hemostatic system, rather than a direct effect of the agent itself...
  20. ncbi request reprint Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk
    Alisa S Wolberg
    Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, USA
    Blood 101:3008-13. 2003
    ..We hypothesize that this alteration in fibrin clot structure is an important determinant of the risk of thrombosis...
  21. ncbi request reprint Recombinant factor VIIa: how safe is the stuff?
    Harold R Roberts
    Can J Anaesth 52:8-11. 2005
  22. ncbi request reprint Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations
    Christine L Kempton
    University of North Carolina, Chapel Hill, NC 27599 7035, USA
    Arterioscler Thromb Vasc Biol 25:861-6. 2005
    ....
  23. ncbi request reprint Fathers of modern coagulation
    Dougald M Monroe
    UNC Medical School Hematology Oncology, 932 Mary Ellen Jones, CB 7035 Chapel Hill, North Carolina 27599 7035, USA
    Thromb Haemost 98:3-5. 2007
  24. ncbi request reprint High dose factor VIIa improves clot structure and stability in a model of haemophilia B
    Alisa S Wolberg
    Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, NC 27599 7525, USA
    Br J Haematol 131:645-55. 2005
    ....
  25. ncbi request reprint Novel therapeutic agents in the management of hemorrhage and thrombosis
    Christine L Kempton
    Aflac Cancer Center and Blood Disorders Service and Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Cardiovasc Hematol Agents Med Chem 4:319-34. 2006
    ..These agents and others will be discussed in detail with respect to mechanism of action, clinical efficacy and safety...
  26. ncbi request reprint Cutaneous wound healing is impaired in hemophilia B
    Maureane Hoffman
    Laboratory Service 113, Durham Veterans Affairs Medical Center, 508 Fulton St, Durham, NC 27705, USA
    Blood 108:3053-60. 2006
    ..Our findings have significant implications for treatment of patients with hemophilia, and also highlight the importance of rapidly establishing hemostasis following trauma or surgery...
  27. ncbi request reprint Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces
    Julie A Oliver
    Duke University and the Durham VA Medical Hospital, Durham, NC, USA
    Blood 100:539-46. 2002
    ..From the studies reported here, we conclude that in vivo, despite the important role of the protein C system in regulating thrombosis, activated protein C does not serve as a primary regulator of platelet-dependent thrombin generation...
  28. ncbi request reprint Platelets and thrombin generation
    Dougald M Monroe
    Center for Thrombosis and Hemostasis, University of North Carolina, Chapel Hill 27599 7035, USA
    Arterioscler Thromb Vasc Biol 22:1381-9. 2002
    ..Individual differences in platelet thrombin generation might be accounted for by differences in platelet-binding proteins...
  29. ncbi request reprint Mechanism of action of high-dose factor VIIa: points of agreement and disagreement
    Dougald M Monroe
    Arterioscler Thromb Vasc Biol 23:8-9; discussion 10. 2003
  30. ncbi request reprint Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage
    Geoffrey A Allen
    Center for Thrombosis and Hemostasis and Pediatric Hematology Oncology, University of North Carolina School of Medicine, Chapel Hill 27599 7220, USA
    Can J Anaesth 49:S7-14. 2002
    ..We have attempted to reconcile the various proposed mechanisms of action of rFVIIa with its apparent efficacy in such diverse clinical settings...
  31. ncbi request reprint Monitoring coagulation and the clinical effects of recombinant factor VIIa
    Don A Gabriel
    Division of Hematology, University of North Carolina, Chapel Hill, MC, USA
    Semin Hematol 41:20-4. 2004
    ..Using clinical examples, the utility of these technologies is assessed and conclusions drawn about the most useful diagnostic measures for monitoring hemostasis...
  32. ncbi request reprint Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo
    Tong Gui
    Department of Biology, University of North Carolina at Chapel Hill, 27599 3280, USA
    Blood 100:153-8. 2002
    ..Our results suggest that factor IX Gla-domain mediated binding to endothelial cells/collagen IV plays a role in controlling factor IX concentration in the blood...
  33. ncbi request reprint Oscar Ratnoff: his contributions to the golden era of coagulation research
    Harold R Roberts
    Center for Thrombosis and Hemostasis, University of North Carolina, 932 Mary Ellen Jones Building Campus Box 7035, Chapel Hill, NC, USA
    Br J Haematol 122:180-92. 2003
  34. ncbi request reprint Platelet-dependent action of high-dose factor VIIa
    Maureane Hoffman
    Blood 100:364-5; author reply 365. 2002
  35. ncbi request reprint Thrombin generation in vascular tissue
    A Pathak
    Division of Cardiology, Hematology and Cardiothoracic Surgery and Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, NC 27599 7075, USA
    J Thromb Haemost 4:60-7. 2006
    ..Classically, it is thought that the vast majority of thrombin is generated on the surface of platelets, however, thrombotic events occur in patients despite treatment with potent antiplatelet agents...
  36. ncbi request reprint Hemophilia care in the 21st century
    Christine L Kempton
    Division of Hematology Oncology at the University of North Carolina, Chapell Hill, NC 27599 7035, USA
    Clin Adv Hematol Oncol 2:733-40. 2004
  37. ncbi request reprint Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo
    D M Monroe
    Department of Medicine, University of North Carolina, Chapel Hill
    Blood 73:1540-4. 1989
    ..Further, our data suggest that the mutation results in a molecule that interacts with components of the extrinsic pathway to give a prolonged ox brain prothrombin time...
  38. ncbi request reprint Overview of anticoagulant drugs for the future
    Stephan Moll
    Department of Medicine, Division of Hematology Oncology, Center for Thrombosis and Hemostasis, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7035, USA
    Semin Hematol 39:145-57. 2002
    ....
  39. ncbi request reprint More information on patients with factor XI deficiency
    Harold R Roberts
    Anesthesiology 101:1253-4. 2004
  40. ncbi request reprint Vitamin K supplementation during oral anticoagulation: concerns
    Daniel W Stafford
    Blood 109:3607; author reply 3607-8. 2007
  41. ncbi request reprint A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects
    Marianne J Fridberg
    Novo Nordisk A S, Krogshoejvej 55, DK 2880 Bagsvaerd, Denmark
    Blood Coagul Fibrinolysis 16:259-66. 2005
    ..In conclusion, the pharmacokinetics of rFVIIa in Caucasian and Japanese subjects are similar, and no safety issues were identified...

Research Grants12

  1. CELL MEDIATED HEMOSTASIS
    Harold Roberts; Fiscal Year: 1999
    ....
  2. CELL MEDIATED HEMOSTASIS
    Harold Roberts; Fiscal Year: 1993
    ....
  3. CELL MEDIATED HEMOSTASIS
    Harold Roberts; Fiscal Year: 2004
    ....